Centessa Pharmaceuticals plc (CNTA)

9,47 -0,08 (-0,84%) Alla chiusura: 04:00PM EDT

Centessa Pharmaceuticals plc

1 Ashley Road
3rd Floor
Altrincham WA14 2DT
United Kingdom

https://www.centessa.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 76

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Saurabh Saha M.D., Ph.D.	CEO & Director	1,04M	N/D	1976
Dr. David M. Chao Ph.D.	Chief Administrative Officer	710,3k	N/D	1968
Dr. Antoine Yver M.D., M.Sc.	Executive VP & Chairman of Development	773,14k	N/D	1958
Dr. Gregory M. Weinhoff M.B.A., M.D.	Principal Accounting Officer & CFO	655k	N/D	1971
Ms. Tia L. Bush	Chief Technology & Quality Officer	N/D	N/D	1971
Ms. Kristen K. Sheppard Esq., J.D.	Senior Vice President of Investor Relations & Corporate Communications	N/D	N/D	N/D
Mr. Iqbal J. Hussain L.L.B.	General Counsel, Chief Compliance Officer & Corporate Secretary	N/D	N/D	1981
Ms. Karen M. Anderson	Chief People Officer	N/D	N/D	1968
Dr. Harris L. Rotman Ph.D.	Senior Vice President of Regulatory Affairs	N/D	N/D	N/D
Dr. Patrick Yue M.D.	Senior VP of Clinical Development & Innovative Medicines	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Centessa Pharmaceuticals plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.